March 23, 2025

Avidity Biosciences Appoints New Chief Legal Officer

Community Resource Consultants Inc. (CRCI)

Community Resource Consultants Inc. (CRCI) is a Michigan-based organization specializing in trauma rehabilitation medical case management. With over 34 years of experience, CRCI is dedicated to empowering survivors of catastrophic auto accidents to regain control of their lives and achieve both physical and emotional well-being. Their team of Licensed Master Social Workers (LMSWs) and Registered Nurses (RNs) are experts in navigating the complexities of today’s healthcare system, ensuring that survivors receive the necessary services for their recovery and rehabilitation. CRCI’s core values include advocacy, people, knowledge, and dependability, reflecting their commitment to being leading advocates and facilitators of long-term collaborative care.

News Summary

Avidity Biosciences has announced the appointment of John B. Moriarty, Jr. as their Chief Legal Officer, effective immediately. With nearly 30 years of legal experience, Moriarty will guide the company as it progresses in RNA therapeutics. Analysts are optimistic about Avidity’s direction, maintaining buy ratings and strong price targets. Specialized in Antibody Oligonucleotide Conjugates (AOCs™), Avidity aims to advance treatments for rare muscle diseases. Moriarty’s legal expertise is expected to bolster Avidity’s growth and advocacy for patient-centered strategies.

Exciting Changes at Avidity Biosciences as They Appoint a New Chief Legal Officer

In the fast-paced world of biotech, changes can bring about fresh opportunities. Avidity Biosciences is making headlines with the appointment of John B. Moriarty, Jr. as their new Chief Legal Officer, effective immediately. Moriarty, equipped with nearly 30 years of legal expertise, promises to steer the company during a transformative period as they push the boundaries in RNA therapeutics.

Analyst Ratings Roar in Favor of Avidity

The buzz around Avidity is palpable as analysts issue positive ratings for the company. Ritu Baral from TD Cowen maintains a Buy rating on Avidity shares, targeting a price of $78.00. This highly favorable view comes as a result of CEO Sarah Boyce’s strategy of keeping patients at the center of drug discovery. Under her leadership, Avidity emphasizes the importance of patient advocacy, aiming to incorporate it into their future growth strategy.

Meanwhile, Scotiabank also chimed in, upholding their Buy rating with a price target of $70.00. It’s interesting to note that Ritu Baral boasts an average return of 9.1% on her stock recommendations, with a success rate of nearly 46%. This is a strong testament to the positive outlook surrounding Avidity Biosciences.

Avidity’s Focus: Powerful RNA Therapeutics

So, what sets Avidity Biosciences apart? They specialize in a groundbreaking class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™). Recently, they achieved a significant milestone by demonstrating the first-ever successful targeted delivery of RNA directly into muscle cells. This is a remarkable feat that positions Avidity as a leader in the company’s focus on three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD).

Meet John B. Moriarty, Jr.

John B. Moriarty joins Avidity at an unusually exciting time. His background includes serving previously as Chief Legal Officer for several reputable companies, such as Mirati Therapeutics and Olema Oncology, among others. His rich experience also features roles as General Counsel at Portola Pharmaceuticals and Alexion Pharmaceuticals. With his strong legal background, Moriarty is expected to play a key role in advancing Avidity’s clinical development programs.

In his new role, he takes the reins from John W. Wallen III, who had been General Counsel since 2019 and will transition to a consulting role by year-end. Moriarty’s impressive credentials include a B.A. from the University of Virginia and a J.D. from the University of Georgia School of Law, where he graduated cum laude.

The Road Ahead for Avidity

As Avidity moves forward, the company is poised to continue leading the way in RNA therapeutics. The team is eager to develop pioneering treatment solutions that can potentially transform patients’ lives. For both the new Chief Legal Officer and the rest of the leadership team, the focus remains clear: to integrate patient advocacy into their strategic plan for future growth and to continue to advance their innovative research.

So, while the world of biotech continues to grow and evolve, Avidity Biosciences is certainly a company to watch, especially with Moriarty now part of the team. Who knows what other breakthroughs this company will achieve? Keep your ears open and your eyes peeled as they work towards revolutionizing RNA therapeutics!